These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 10901448

  • 1. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M, Béhé M, Guhlke S, Otte R, Bender H, Maecke HR, Biersack HJ.
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [Abstract] [Full Text] [Related]

  • 2. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.
    Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.
    Eur J Nucl Med; 2000 Sep; 27(9):1318-25. PubMed ID: 11007513
    [Abstract] [Full Text] [Related]

  • 3. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
    Decristoforo C, Melendez-Alafort L, Sosabowski JK, Mather SJ.
    J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
    [Abstract] [Full Text] [Related]

  • 4. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
    Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychlinski C, Mather SJ, Moncayo R.
    J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
    [Abstract] [Full Text] [Related]

  • 5. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA, Hofland LJ, van der Pluijm M, van Koetsveld PM, de Jong M, Setyono-Han B, Bakker WH, Kwekkeboom DJ, Visser TJ, Lamberts SW.
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
    Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR.
    J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
    [Abstract] [Full Text] [Related]

  • 7. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide.
    Stahl A, Meisetschläger G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, Schwaiger M.
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):45-52. PubMed ID: 16151771
    [Abstract] [Full Text] [Related]

  • 8. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ, Kooij PP, Bakker WH, Mäcke HR, Krenning EP.
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [Abstract] [Full Text] [Related]

  • 9. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
    Helisch A, Förster GJ, Reber H, Buchholz HG, Arnold R, Göke B, Weber MM, Wiedenmann B, Pauwels S, Haus U, Bouterfa H, Bartenstein P.
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
    [Abstract] [Full Text] [Related]

  • 10. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, Pauwels S, Jamar F.
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [Abstract] [Full Text] [Related]

  • 11. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
    Grimes J, Celler A, Birkenfeld B, Shcherbinin S, Listewnik MH, Piwowarska-Bilska H, Mikolajczak R, Zorga P.
    J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo evaluation of copper-64-octreotide conjugates.
    Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ.
    J Nucl Med; 1995 Dec; 36(12):2315-25. PubMed ID: 8523125
    [Abstract] [Full Text] [Related]

  • 13. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.
    Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, Virgolini IJ.
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):364-72. PubMed ID: 23151915
    [Abstract] [Full Text] [Related]

  • 14. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Decristoforo C, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R, Mather SJ.
    Eur J Nucl Med; 2000 Oct; 27(10):1580. PubMed ID: 11083550
    [No Abstract] [Full Text] [Related]

  • 15. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours.
    Gaertner FC, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh RA, Sinnes JP, Rösch F, Essler M.
    Nucl Med Biol; 2019 Oct; 76-77():1-9. PubMed ID: 31520872
    [Abstract] [Full Text] [Related]

  • 16. Comparative analysis of 99mTc-depreotide and 99mTc-EDDA/HYNIC-TOC thorax scintigrams acquired for the purpose of differential diagnosis of solitary pulmonary nodules.
    Płachcińska A, Mikołajczak R, Kozak J, Rzeszutek K, Kuśmierek J.
    Nucl Med Rev Cent East Eur; 2006 Oct; 9(1):24-9. PubMed ID: 16791800
    [Abstract] [Full Text] [Related]

  • 17. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC.
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [Abstract] [Full Text] [Related]

  • 18. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G.
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [Abstract] [Full Text] [Related]

  • 19. Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed with 99mTc-EDDA/HYNIC-TOC SPECT.
    Madrzak D, Mikołajczak R, Kamiński G.
    Nucl Med Rev Cent East Eur; 2016 Sep; 19(2):88-92. PubMed ID: 27479886
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.